{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:24:41Z","timestamp":1780593881077,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13104-019-4507-6","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T05:02:31Z","timestamp":1565586151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2529-5664","authenticated-orcid":false,"given":"Trygve","family":"Holm\u00f8y","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rre","family":"Fevang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Benee","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Spigset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"B\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"4507_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","volume":"32","author":"S Faissner","year":"2018","unstructured":"Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs. 2018;32:269\u201387.","journal-title":"CNS Drugs"},{"key":"4507_CR2","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.4049\/jimmunol.1301926","volume":"191","author":"X Zhang","year":"2013","unstructured":"Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191:5867\u201374.","journal-title":"J Immunol"},{"key":"4507_CR3","unstructured":"European Medical Agency. Lemtrada summary of products characteristics. https:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003718\/human_med_001678.jsp&mid=WC0b01ac058001d124 . Accessed 19 Mar 2019."},{"key":"4507_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.msard.2018.05.014","volume":"24","author":"LJW Canham","year":"2018","unstructured":"Canham LJW, Manara A, Fawcett J, et al. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis. Mult Scler Relat Disord. 2018;24:38\u201341.","journal-title":"Mult Scler Relat Disord"},{"key":"4507_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12883-017-0848-8","volume":"17","author":"T Holmoy","year":"2017","unstructured":"Holmoy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab\u2014a case for better preventive strategies. BMC Neurol. 2017;17:65.","journal-title":"BMC Neurol"},{"key":"4507_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40360-018-0267-5","volume":"19","author":"AZ Myro","year":"2018","unstructured":"Myro AZ, Bjerke G, Zarnovicky S, Holmoy T. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report. BMC Pharmacol Toxicol. 2018;19:75.","journal-title":"BMC Pharmacol Toxicol"},{"key":"4507_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.msard.2018.04.014","volume":"23","author":"KG Yiannopoulou","year":"2018","unstructured":"Yiannopoulou KG, Papadimitriou D, Anastasiou AI, Siakantaris M. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion. Mult Scler Relat Disord. 2018;23:15\u20136.","journal-title":"Mult Scler Relat Disord"},{"key":"4507_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40478-016-0352-1","volume":"4","author":"I Metz","year":"2016","unstructured":"Metz I, Rieckmann P, Kallmann BA, Bruck W. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis. Acta Neuropathol Commun. 2016;4:81.","journal-title":"Acta Neuropathol Commun"},{"key":"4507_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1212\/WNL.0000000000005420","volume":"90","author":"M Saarela","year":"2018","unstructured":"Saarela M, Senthil K, Jones J, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018;90:849\u201351.","journal-title":"Neurology"},{"key":"4507_CR10","unstructured":"US Food and Drug Administration 2005. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. https:\/\/www.fda.gov\/files\/drugs\/published\/Good-Pharmacovigilance-Practices-and-Pharmacoepidemiologic-Assessment-March-2005.pdf . Accessed 15 May 2019."},{"key":"4507_CR11","unstructured":"The Uppsala Monitoring Centre. The Use of the WHO-UMC system for standardised casse causality assesment. https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf . Accessed 21 Mar 2019."},{"key":"4507_CR12","doi-asserted-by":"publisher","first-page":"e1548","DOI":"10.1212\/WNL.0000000000005422","volume":"90","author":"D Croteau","year":"2018","unstructured":"Croteau D, Flowers C, Kulick CG, Brinker A, Kortepeter CM. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab. Neurology. 2018;90:e1548\u201352.","journal-title":"Neurology"},{"key":"4507_CR13","unstructured":"US Food and Drug Administration 2018. FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). Safety Announc. https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM626584.pdf . Accessed 14 Mar 2019."},{"key":"4507_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(19)30076-6","volume":"18","author":"CJ Azevedo","year":"2019","unstructured":"Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol. 2019;18:329\u201331.","journal-title":"Lancet Neurol"},{"key":"4507_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.msard.2017.09.028","volume":"18","author":"D Baker","year":"2017","unstructured":"Baker D, Giovannoni G, Schmierer K. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment. Mult Scler Relat Disord. 2017;18:181\u20133.","journal-title":"Mult Scler Relat Disord"},{"key":"4507_CR16","doi-asserted-by":"crossref","first-page":"P2.103","DOI":"10.1212\/WNL.86.16_supplement.P2.103","volume":"86","author":"P Rieckmann","year":"2016","unstructured":"Rieckmann P, Lenz A, Hoffmann M, Poske U, Behr K, Kallmann B. Fatal autoimmune hemolytic anemia associated with alemtuzumab in a MS patient with severe relapsing remitting disease course and prior immune therapies. Neurology. 2016;86:P2.103.","journal-title":"Neurology"},{"key":"4507_CR17","unstructured":"Bundes\u00e4rztekammer. Arzneimittelkommission der Deutschen \u00c2rzteschaft. Theraprefrakt\u00e4re Autoimmunthrombozytopenie nach Alemtuzumab zur Behandlung einer Multiplen Sklerose. Deutsche Arzteblatt 2017;114:A2175\u20136."},{"key":"4507_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017;74:961\u20139.","journal-title":"JAMA Neurol"},{"key":"4507_CR19","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1212\/NXI.0000000000000228","volume":"3","author":"K Thomas","year":"2016","unstructured":"Thomas K, Eisele J, Rodriguez-Leal FA, Hainke U, Ziemssen T. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurol Neuroimmunol Neuroinflam. 2016;3:e228.","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"4507_CR20","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1172\/JCI119110","volume":"98","author":"MG Wing","year":"1996","unstructured":"Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a\/CD18 (LFA-1) on NK cells. J Clin Invest. 1996;98:2819\u201326.","journal-title":"J Clin Invest"},{"key":"4507_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518816612","author":"A Cuker","year":"2019","unstructured":"Cuker A, Bass AD, Nadj C, et al. Immune thrombocytopenia in alemtuzumab-treated MS patients: incidence, detection, and management. Mult Scler. 2019. https:\/\/doi.org\/10.1177\/1352458518816612 .","journal-title":"Mult Scler"},{"issue":"Suppl C","key":"4507_CR22","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","volume":"20","author":"SA Goldman","year":"1998","unstructured":"Goldman SA. Limitations and strengths of spontaneous reports data. Clin Therap. 1998;20(Suppl C):C40\u20134.","journal-title":"Clin Therap"},{"key":"4507_CR23","unstructured":"Coles A, Robertson N, Al-Araji A et al. Association of British neurologist 2017. Guidance on the prevention of Listeria infection after alemtuzumab treatment of multiple sclerosis. https:\/\/www.theabn.org\/news\/new-guidelines-on-the-prevention-of-listeria-infection.html . Accessed 15 May 2019."}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4507-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-019-4507-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4507-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T18:32:31Z","timestamp":1721586751000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-019-4507-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4507"],"URL":"https:\/\/doi.org\/10.1186\/s13104-019-4507-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11268\/v1","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"8 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to Norwegian regulations informed consent and approval from ethics committee are not needed for this report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No information that could allow identification of patients are included. Consent to publish from patients are therefore not necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T Holm\u00f8y has received unrestricted research grants to his institution and\/or scientific advisory board or speakers honoraria from Biogen, Sanofi, Merck, Novartis, Roche, Santen and Teva; and has participated in clinical trials organized by Biogen, Merck and Roche. L B\u00f8 has received unrestricted research grants to his institution and\/or scientific advisory board or speakers honoraria from Biogen, Genzyme, Merck, Novartis, Roche and Teva; and has participated in clinical trials organized by Biogen, Merck, Novartis and Roche, and has served as expert witness in litigation for Mylan. B Fevang has received spakers honoraria from MSD and Shire. D Benee Olsen and O Spigset has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"497"}}